KarenRuthRabinMDPhD

Pediatric Hematology & Oncology • Houston, TX

Professor, Pediatrics, Baylor College of Medicine

Join to view full profile

Dr. Rabin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rabin's full profile

Already have an account?

Office
1102 Bates Ave Suite 750.00
Texas Childrens Cancer Center
Houston, TX 77030
Phone+1 832-822-4242

Fax+1 832-825-1206

Summary

Dr. Karen Rabin is a medical professional based in Houston, TX, specializing in Pediatric Hematology & Oncology. She completed her Pediatric Hematology/Oncology fellowship at Lucile Packard Children's Hospital/Stanford University School of Medicine in 2004, following the completion of her Pediatrics residency at the University of California San Francisco School of Medicine in 2001. Dr. Rabin is Director of the Leukemia Program at Texas Children's Cancer Center and has significant experience in hematologic malignancies, particularly acute lymphoblastic leukemia (ALL). She has contributed to pediatric oncology research through numerous publications and has been involved in multiple clinical trials focused on therapies for childhood ALL.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Hematology/Oncology, 2001 - 2004
University of California (San Francisco)Residency, Pediatrics, 1998 - 2001
University of California San Francisco School of MedicineClass of 1998

Certifications & Licensure

CA State Medical License 2000 - Present
TX State Medical License 2006 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management.
Jennifer A Belsky, Ashley Chavana, Ankona Banerjee, Mark Zobeck, Eric S Schafer
Pediatric Blood & Cancer. 2025-01-01
A transgenic mouse model of Down syndrome acute lymphoblastic leukemia identifies targetable vulnerabilities.
Jacob J Junco, Max Rochette, Michelle Alozie, Raushan Rashid, Maci Terrell
Haematologica. 2024-12-01
Cerebral Sinus Venous Thrombosis in Pediatric Acute Lymphoblastic Leukemia: Incidence, Clinical Characteristics, and Long-term Neurologic Outcomes.
Lindsay Johnson-Bishop, Cemal Karakas, Stephen F Kralik, Clay T Cohen, Mark Zobeck
Journal of Child Neurology. 2024-11-01

Abstracts/Posters

Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic ...
Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia
Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Pa...
Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN)
Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pharmacological Inhibition of MAP2K7 Induces Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia
Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Novel Short Latency, High Penetrance Model of KRAS Mutation-Driven T-Cell Acute Lymphoblastic Leukemia
Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Germline RUNX1 Variation and Predisposition to T-Cell Acute Lymphoblastic Leukemia in Children
Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the ChildrenÍs...
Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Delays in Therapy Do Not Impact Survival in Childhood Acute Lymphoblastic Leukemia: A Report from the Learn Consortium
Karen R. Rabin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Authored Content

Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731December 2024

Press Mentions

Dasatinib Superior to Imatinib in Pediatric ALLJanuary 16th, 2020
Novel Approach Identifies Factors Linked to Poor Treatment Outcomes in Acute Lymphoblastic LeukemiaOctober 24th, 2019
Dasatinib Beats Imatinib in Childhood LeukemiaMarch 14th, 2020
Join now to see all